TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX’s initial focus is on the treatment of drug-resistant TB.

A study of tuberculosis patients in six Jakarta hospitals has revealed up to 13 per cent of them had fungal lung infection – or aspergillosis – at the end of their treatment.

Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.